Key Highlights
- AIRNA secures $60M in oversubscribed Series A financing.
- Funding led by Forbion with key investments from Ono Venture, Alexandria, ARCH Venture Partners, and ND Capital.
- Funds to advance lead product for alpha-1 antitrypsin deficiency (AATD) to clinical trials.
- Appointment of Josh Brumm, General Partner at Forbion, to AIRNA’s Board of Directors.
- Development of RNA therapeutics through the RESTORE+™ platform for precise RNA editing.
Source: Business Wire
Notable Quotes
- “This Series A financing brings together a distinctive syndicate of investors to support AIRNA’s vision of transforming lives by realizing the therapeutic potential of base editing for the masses.” — Kris Elverum, President and Chief Executive Officer at AIRNA
- “AIRNA has a differentiated approach to delivering life-changing outcomes for patients with AATD and other severe diseases.” — Josh Brumm, General Partner at Forbion
SoHC's Take
The closing of AIRNA’s $60 million Series A financing marks a significant milestone in the biotech industry, particularly in the field of RNA editing therapeutics. This robust investment underscores the confidence in AIRNA’s innovative RESTORE+™ platform and its potential to address diseases with high unmet needs. With the new funding, AIRNA is well-positioned to advance its lead product candidate for alpha-1 antitrypsin deficiency into clinical trials and further develop its promising pipeline. The appointment of seasoned biotech leader Josh Brumm to the Board of Directors further strengthens AIRNA’s strategic direction, enhancing its potential to become a leader in genetic medicines.
